マインド メディシン マインドメッドのニュース一覧

10-Q：四半期報告書

SEC4分前

Mind Medicine GAAP EPS of -$0.27 Beats by $0.03

Seeking Alpha26分前

Massachusetts Psychedelics Legalization Initiative Poised to Fail

Seeking Alpha11/06 14:55

马萨诸塞州或成合法化下一站，迷幻药概念股迎投资良机？

智通財経11/04 19:47

Legalizing Psychedelics: Is Massachusetts Next?

Seeking Alpha11/04 18:27

MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update

Businesswire10/24 19:00

FDA Is Said to See "Path Forward" for Ecstasy-based Drug

Seeking Alpha10/19 21:40

Bright Minds Rally Ends as Psychedelic Stocks Extend Volatility

Seeking Alpha10/17 01:55

Mind Medicine Assumed With an Outperform at Leerink

Yahoo Finance10/13 06:05

Leerink Partnersはマインド メディシン マインドメッド(MNMD.US)のレーティングを強気にし、目標株価を20ドルにした

Leerink PartnersのアナリストMarc Goodmanは$Mind Medicine(MNMD.US)$のレーティングを強気にし、目標株価を20ドルにした。TipRanksのデータによると、このアナリストの最近1年間の的中率は48.0%、平均リターンは6.5%である。注 TipRanksは、金融アナリストの分析データと、アナリストの的中率および平均リターンに関する情報を提供している独

Futuニュース10/12 06:31

Mind Medicine's Chief Medical Officer Sells Shares Worth Over $41,000

Investing09/26 08:34

Mind Medicine Is Maintained at Buy by Canaccord Genuity

Dow Jones09/16 22:28

MindMed Announces New Employee Inducement Grants

Businesswire09/10 04:01

Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration

Benzinga09/06 00:53

KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer

Businesswire09/04 20:00

MindMed to Participate in September Investor Conferences

Businesswire09/04 19:00

HC Wainwright & Co. Maintains Buy on Mind Medicine, Raises Price Target to $55

Benzinga08/29 20:02

Mind Medicine Analyst Ratings

Benzinga08/29 20:00

Trials for Psychedelic Drug Candidate for PTSD Under Scrutiny by FDA - Report

Seeking Alpha08/24 06:34

Lykos Laying off 75% of Workforce Following FDA Rejection of Psychedelic Drug for PTSD

Seeking Alpha08/16 03:02